As the pharmaceutical industry advances toward low global warming potential (GWP) propellants like HFA152a and HFO1234ze(E), understanding material compatibility becomes critical, especially when it comes to leachables from common device components.
In a recent evaluation, a group of pulmonary experts at Kindeva assessed the extractable levels associated with various polybutylene terephthalate (PBT) suppliers in pressurized metered dose inhaler (pMDI) formulations containing ethanol and low-GWP propellants. The study was designed to simulate worst-case conditions and generate actionable insights for development teams reformulating with emerging propellant systems.
The findings reinforce the importance of careful material selection and formulation control during the transition to sustainable pMDI technologies:
- Propellant choice affects extractable levels
- Increasing ethanol concentration increases leachables
- PBT grade influences extractable output
- Oligomer presence may impact performance
Understanding the interactions between propellant, co-solvent and material grade is essential for ensuring product stability, safety and compliance as low-GWP formulations progress toward commercialization.
Curious about the full impact of propellant, ethanol and material selection on leachables? Explore the full poster presentation.
Connect with Kindeva to discover how our end-to-end expertise helps future-proof your low-GWP inhalation products by mitigating extractables risk and accelerating sustainable pMDI development.
Access this content
Fields marked with a * are required.
Related resources
Explore our other resources to discover valuable insights on the latest trends in drug delivery.
Career journeys blog 3: Lauren Harrison
In this story, we meet Lauren Harrison, a formulation scientist who began her path as an apprentice and has spent the last decade building a career rooted in curiosity, hands-on learning and collaboration.
Learn More
Navigating the transition to next-generation propellants for pMDIs | On-demand webinar
Regulators, health systems and patients expect meaningful progress on sustainability. For pressurized metered dose inhalers (pMDIs), this means planning the transition to low global warming potential (low-GWP) next-generation propellants (NGPs) now, not at the end of the decade. In this webinar with Pharmaceutical Technology, Craig Somerville, Senior Vice President of Kindeva’s pMDI business unit, shares […]
Learn More
Beyond the contract: Driving transformational partnerships with manufacturing… and more
Achieving scientific breakthroughs is just one hurdle in today’s drug development and manufacturing process aimed at improving patient outcomes. Bringing a new therapy to market requires meticulous execution and clear communication at every step. Unfortunately, even the most groundbreaking scientific advancements can be delayed or even entirely abandoned due to poor performance from partners. This […]
Learn More
Why Kindeva: Analytical and regulatory services
Overcome complex analytical and regulatory challenges with a partner dedicated to your product’s success. Our specialist expertise helps you navigate testing, compliance, and quality to advance your project from concept to commercialization. Download our one-pager for a closer look at our integrated approach, including: An overview of our comprehensive, phase-appropriate analytical services. How our regulatory […]
Learn More
Career journeys blog 2: Oliver Ingham
In this latest installment, we meet Oliver Ingham, an analytical chemist whose curiosity and problem-solving skills have shaped his journey from academic research to coordinating analytical development services at Kindeva.
Learn More
Career journeys blog 1: Holly Dowdle
When Holly Dowdle first joined Kindeva as a student intern, she experienced a workplace that valued both curiosity and collaboration. It was an environment where asking questions was encouraged and development was part of everyday work, not something that happened on the sidelines.
Learn More
A bridge between design and delivery: Exploring sterile fill finish integration for injectable product success
The global sterile injectable contract manufacturing market is experiencing rapid growth, driven by increasing demand for advanced biologics, glucagon-like peptide-1 (GLP-1) therapies and other injectables. These products pair drugs with delivery devices to support patient-centric care, but their manufacturing presents unique challenges. Programs often require specialized environments, such as cold-chain storage and low-volume fills, and […]
Learn More
Going beyond manufacturing: The Kindeva customer experience
Going beyond manufacturing: The Kindeva customer experience As development timelines tighten and product complexity grows, the quality of CDMO partnerships has transformed into a critical success factor. In today’s high-stakes landscape, drug developers need more than technical execution. They need partners who embed early, stay aligned and help navigate every phase of the product lifecycle. […]
Learn More
Built for better tomorrows: How Bridgeton delivers for patients
Kindeva’s Bridgeton facility offers a purpose-built solution for the complex and evolving landscape of injectable drugs. The facility was specifically designed to address challenges in sterile injectable manufacturing, such as the siloed approaches that often separate core functions like formulation and fill finish. By co-locating these functions and operating within integrated systems, the Bridgeton model […]
Learn MoreLet’s transform tomorrow together
Every patient deserves a brighter tomorrow. As your strategic partner, we are dedicated to building your lasting legacy and helping you fast-track healthier tomorrows. You dream it, we deliver it.